Literature DB >> 11701674

The IGF-I generation test revisited: a marker of GH sensitivity.

C K Buckway1, J Guevara-Aguirre, K L Pratt, C P Burren, R G Rosenfeld.   

Abstract

IGF-I generation tests were developed over 20 yr ago and are currently used in differentiating GH insensitivity (GHI) from other disorders characterized by low serum IGF-I. Nevertheless, generation tests have never been adequately characterized, and insufficient normative data are available. One hundred and ninety-eight subjects [including normal subjects; subjects with GHI, GH deficiency (GHD), and idiopathic short stature (ISS); and heterozygotes for the E180 splice GH receptor mutation] were randomized to self-administration of either a high (0.05 mg/kg x d) or a low (0.025 mg/kg x d) dose of GH for 7 d. After a 2-wk washout period, they received the alternate dose. Samples were collected on d 1, 5, and 8 of each treatment period. In normal individuals, IGF-I generation was GH dependent at all ages, and little advantage was observed in using the higher dose of GH or extending beyond the d 5 sample. Some GHD patients had IGF-I levels, both baseline and stimulated, that overlapped levels in the verified GHI patients. Subjects heterozygous for the E180 GH receptor splice mutation did not show a decreased responsiveness to GH. ISS patients had low-normal IGF-I levels that did not stimulate beyond the baseline normative ranges for age. These data provide the first large scale effort to provide preliminary normative IGF generation data and evaluate the GH sensitivity of patients with GHI, GHD, and ISS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701674     DOI: 10.1210/jcem.86.11.8019

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

Review 1.  Growth hormone insensitivity: diagnostic and therapeutic approaches.

Authors:  S Kurtoğlu; N Hatipoglu
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

2.  The utility of the IGF-I generation test in children with chronic kidney disease.

Authors:  Amira Al-Uzri; Rita D Swinford; Thuan Nguyen; Randall Jenkins; Anthony Gunsul; Svetlana S Kachan-Liu; Ron Rosenfeld
Journal:  Pediatr Nephrol       Date:  2013-09-07       Impact factor: 3.714

Review 3.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.

Authors:  Madeliene Stump; Deng-Fu Guo; Ko-Ting Lu; Masashi Mukohda; Martin D Cassell; Andrew W Norris; Kamal Rahmouni; Curt D Sigmund
Journal:  Endocrinology       Date:  2016-08-30       Impact factor: 4.736

5.  A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

Authors:  Francesco Saccà; Mario Quarantelli; Carlo Rinaldi; Tecla Tucci; Raffaele Piro; Gaetano Perrotta; Barbara Carotenuto; Angela Marsili; Vincenzo Palma; Giuseppe De Michele; Arturo Brunetti; Vincenzo Brescia Morra; Alessandro Filla; Marco Salvatore
Journal:  J Neurol       Date:  2011-06-25       Impact factor: 4.849

Review 6.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

7.  Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone.

Authors:  Suk See De Ravin; Elaine Shum; Kol A Zarember; Geoffrey Rezvani; Ron G Rosenfeld; Constantine A Stratakis; Harry L Malech
Journal:  J Pediatr Endocrinol Metab       Date:  2008-11       Impact factor: 1.634

Review 8.  Treatment of dwarfism with recombinant human insulin-like growth factor-1.

Authors:  Michael B Ranke; Joachim Wölfle; Dirk Schnabel; Markus Bettendorf
Journal:  Dtsch Arztebl Int       Date:  2009-10-23       Impact factor: 5.594

Review 9.  Regulation of muscle mass by growth hormone and IGF-I.

Authors:  C P Velloso
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

10.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.